ESR1 and breast carcinoma: ORAI3 has gained increased interest because it is overexpressed in cancer, in particular estrogen receptor-expressing breast cancer cells, where it contributes to cancerous properties by inducing calcium influx, phosphorylation of ERK, and expression of c-myc21,23–29.